Pro Bono Bio obtains exclusive licence from PolyTherics to TheraPEG technology

10 September 2012

Anglo-Russian health care group Pro Bono Bio (PBB) and PolyTherics, a privately owned UK company and a provider of solutions for the development of better biopharmaceuticals, have announced further progress on their hematology alliance to produce longer-acting versions of blood factor proteins.

PBB was formed last year in an unusual partnership between the US private equity firm Celtic Pharma Holdings and Russia's state-owned RusNano (The Pharma Letter September 12, 2011). The company was spawned from a three-year British and Russian project developed by Celtic Pharma.

Following an agreement between the parties in May 2012, PBB and PolyTherics undertook a feasibility program to evaluate the use of PolyTherics’ TheraPEG technology to develop a unique long-acting PEGylated form of Factor VIII for the treatment of hemophilia A.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK